Arkolith/Insider Trading/OTLC/Form 4

Trieu Vuong

CHAIRMAN AND CEO, Director, 10% OwnerOncotelic Therapeutics, Inc. (OTLC) · full profile →Form 4 · filed Jul 10, 2025
Net Buying
Open-Market Buys
$2K
Open-Market Sells
$0
Net Open-Market Flow
$2K
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 10, 2025Buy(P)104K$0.01$1K93.3M
Jul 9, 2025Buy(P)1$0.01$093.3M
Jul 8, 2025Buy(P)95K$0.01$94793.4M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001641172-25-018620) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML